Abstract: The invention relates to the field of organic chemistry and medicine, and more particularly to a method of producing synthetic biologically active derivatives of carbopentoxysulfanilic acid. The present method of producing a sodium salt of (2,6-dichlorophenyl)amide carbopentoxysulfanilic acid is characterized in that the reaction mass formed during the production of (2,6-dichlorophenyl)amide carbopentoxysulfanilic acid is agitated in a medium which is acidified with a solution of hydrochloric acid to pH 5-5.5, and the isolated precipitate may be washed with water acidified with a solution of hydrochloric acid to pH 5-5.5. This increases the yield of a sodium salt of (2,6-dichlorophenyl)amide carbopentoxysulfanilic acid to 70% (compared to a prior art yield of 32%) and also increases the purity of the target sodium salt.

Abstract: The invention relates to microbiology, and more particularly to nutrient media used for cultivating bacteria for the subsequent study thereof. A nutrient medium comprising a pancreatic digest of casein, a peptic digest of meat, a heart pancreatic digest, yeast extract, starch and water is characterized in that it additionally contains violuric acid and beef infusion, wherein the ratio of ingredients is (wt %):0.3-1.0 pancreatic digest of casein; 0.1-1.5 peptic digest of meat; 0.1-0.9 heart pancreatic digest; 0.1-2.0 yeast extract, 0.3-0.8 starch; 0.001-0.05 violuric acid; 2.0-15 beef infusion; the remainder water. The nutrient medium can additionally contain 0.3-2.5 wt % agar-agar and/or 1-20 wt % whole or hemolyzed sheep red blood cells and/or 1-20 wt % whole or hemolyzed human red blood cells and/or 1-15 wt % horse blood serum. This provides for the simultaneous growth of the maximum possible number of bacteria present in an inoculate.

Abstract: The invention relates to the liver-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of cell free DNA (cfDNA) accumulated in hepatic porto-sinusoidal circulation and the use of such liver-specific delivery and/or expression for treatment of various diseases and conditions, including cancer and neurodegeneration.

Abstract: The invention relates to microbiology and medicine and can be used to prevent and treat diseases and conditions associated with disruption of normal (autochthonous) microflora (microbiota) in humans or animals. In particular, a solution for recovery or creation of the subject's microflora comprising an active component containing microorganisms isolated from the microflora of the subject or the donor, wherein the active component can be enriched with bacteriophages of said microflora and/or additional microorganisms of the microflora cultivated on a nutrient medium, while the additional microorganisms of the microflora include microorganisms of the microflora that are yet nonculturable in the absence of the host organism, is proposed.

Abstract: The invention relates to pharmacology and can be used for treating liver diseases of various etiologies, inter alia, in combination with other preparations. Claimed is a drug with hepatoprotective activity comprised of 3-(4-bromophenyl)-6,6-dihydroxy-5-hydroxyiminohexahydro-2,4-pyrimidinedione and salts thereof of general formula (I), where X is selected from the group: H, Na, K, or from the group of hydroxyalkylammonia derivatives of general formula (II), where R1, R2 are selected from the group: H, CH3, CH2CH3, CH2CH2OH; R3 is selected from the group: H, CH2OH; and n=1, 2; the drug can be prepared in the form of tablets or capsules for enteral administration; or in the form of a liquid or lyophilized substance for parenteral administration; or in the form of rectal suppositories; or in the form of capsules or tablets, or sweets for sucking; and may additionally contain the hepatoprotector Heptral; or the hepatoprotector Essentiale; or the hepatoprotector ursodeoxycholic acid.

Abstract: The invention relates to antiviral agents and specifically to synthetic biologically-active derivatives, and can be used in the pharmaceutical industry, in medicine, in plant husbandry and in biotechnology. The antiviral agent is based on poly-N1-hydrazino(imino)methyl-1,6-hexanediamine-poly-N1-amino(imino)methyl-1,6-hexane diamine of general formula (1), where: HX is an acid, n=3-20, and m=4-20, and which is active against viruses of humans, animals, plants, bacteria and fungi, said viruses being non-enveloped and enveloped and containing RNA or DNA. The antiviral agent exhibits a broad range of effectiveness, and is active against viruses both in intracellular and extracellular locations.

Abstract: The invention relates to the field of microbiology. A device for determining the sensitivity of microorganisms to antimicrobial drugs is configured in the form of a sterile plate made from a plastic material with indentations and is provided with a hermetically sealing element which covers the sterile plate. The indentations are filled with a solid culture medium containing agar. In different indentations, the culture medium contains antimicrobial drugs or combinations thereof or serves as a control. Between the plate and the hermetically sealing element, the device contains a moisture-absorbing material with a rigid mesh situated therebelow. The device is provided with a transparent protective lid made from a rigid durable plastic.

Abstract: The invention relates to the field of organic chemistry and medicine, and more particularly to synthetic substances of the pyrimidine series, namely 2-chloro-5-phenyl-5H-pyrimido[5?,4?:5,6]pyrano[2,3-d]pyrimidine-4-ol derivatives, having antiviral activity.

Abstract: The invention relates to medicine and to veterinary medicine, and specifically to means for determining the sensitivity of various microorganisms, including bacteria and fungi, to antimicrobial substances. The method for determining the sensitivity of microorganisms to antimicrobial substances comprises taking biological material, incubating microorganisms contained therein on a nutrient medium, introducing an antimicrobial substance to be investigated into the nutrient medium and subsequently assessing the result. A dense, rich nutrient medium is used for cultivating the microorganisms. The antimicrobial substance being investigated is introduced into the nutrient medium prior to cultivation of the microorganisms in a concentration close to the maximum concentration achievable at the location at which the biological material is taken. The sensitivity of the microorganisms to the antimicrobial substance is assessed after the appearance of visible growth of microorganisms in a control culture.

Abstract: The invention relates to the use of deoxyribonuclease (DNase) enzyme for inhibiting progression and for prevention and treatment of neurodegeneration.

Abstract: The invention relates to a novel fungicidal agent in the form of a salt associate having the structural formula shown. The agent can be used for treating diseases caused by fungi, and also for preventing fungal damage to various materials and agricultural products. The present fungicidal agent is an associate of 5-[3,5-dichloro-2-hydroxy benzylidene)amino]-4-hydroxy-1H-pyrimidine-2-on with 1,2,3,4,5-pentahydroxy-6-methylaminohexane and has the formula (I). This fungicidal agent exhibits a broad range of activity and high solubility, which increases the effectiveness of the use thereof in the form of solutions. Compounds were obtained in a crystalline form, and the structure thereof was established by means of magnetic resonance spectra in dimethyl sulfoxide.

Abstract: The invention relates to pharmacology and can be used for treating liver diseases of various etiologies, inter alia, in combination with other preparations. Claimed is a drug with hepatoprotective activity comprised of 3-(4-bromophenyl)-6,6-dihydroxy-5-hydroxyiminohexahydro-2,4-pyrimidinedione and salts thereof of general formula (I), where X is selected from the group: H, Na, K, or from the group of hydroxyalkylammonia derivatives of general formula (II), where R1, R2 are selected from the group: H, CH3, CH2CH3, CH2CH2OH; R3 is selected from the group: H, CH2OH; and n=1, 2; the drug can be prepared in the form of tablets or capsules for enteral administration; or in the form of a liquid or lyophilized substance for parenteral administration; or in the form of rectal suppositories; or in the form of capsules or tablets, or sweets for sucking; and may additionally contain the hepatoprotector Heptral; or the hepatoprotector Essentiale; or the hepatoprotector ursodeoxycholic acid.

Abstract: The invention relates to medicine, and specifically to synthetic biologically active derivatives of carbopentoxysulfanilic acid. The novel substance comprises a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula: Where X is Na, K, NH4; the drug may be contained in tablets, including sublingual tablets, or in capsules, or in suppositories, or in drops, or in mixtures, or in ointments, creams or other forms for application to the skin and mucosae, or in an oral-buccal film, or in a spray, or in a liquid for parenteral administration, or in chewing gum. A preparation having pronounced activity against herpes viruses is thus produced.

Abstract: The invention relates to medicine, namely, to the solutions used for hemostasis. The hemostatic agent, which represents a polyammonia methanediamine chloride of the general formula where: n=1-20, m=1-10, at that n×m?8. The hemostatic agent may be applied in the form of a 0.01-10% aqueous solution. An aqueous solution of the preparation can be used for impregnation of materials used for bleeding arrest, suture material, bandaging material. The hemostatic agent may be used in the composition of a retraction cord, adhesive pastes, vaginal and rectal suppositories, creams, gels, as well as used with microchips that provide slow release of the preparation. The preparation can also be used in eye drops, eye ointments, and lubricants applied to the surface of the catheter. The drug can be used in endodontic treatment, may be injected into a polymer sealer for root canal obturation, as well as locally—by means of electrophoresis.

Abstract: The invention relates to medicine and specifically to methods for treating recurring forms of diseases related to the family of herpes viruses. A method for treating recurring diseases of the skin and mucous membranes caused by HSV-1 and HSV-2 involves applying a preparation to an affected area, said preparation including a base containing 0.5% or 1% of an active substance, namely a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula (I): where X is Na, K, NH4; the preparation is applied twice daily for 3-5 days and, should prodromes appear, a second course of treatment is carried out, in which the preparation is applied 1-2 times daily for 2-3 days; the base containing the active substance can be in the form of a cream, an ointment, a gel, a suspension, suppositories, a patch or a film.

Abstract: The invention relates to a novel fungicidal agent in the form of a salt associate having the structural formula shown. The agent can be used for treating diseases caused by fungi, and also for preventing fungal damage to various materials and agricultural products. The present fungicidal agent is an associate of 5-[3,5-dichloro-2-hydroxy benzylidene)amino]-4-hydroxy-1H-pyrimidine-2-on with 1,2,3,4,5-pentahydroxy-6-methylaminohexane and has the formula (I). This fungicidal agent exhibits a broad range of activity and high solubility, which increases the effectiveness of the use thereof in the form of solutions. Compounds were obtained in a crystalline form, and the structure thereof was established by means of magnetic resonance spectra in dimethyl sulfoxide.

Abstract: The invention relates to the field of organic chemistry and medicine, and more particularly to a method of producing synthetic biologically active derivatives of carbopentoxysulfanilic acid. The present method of producing a sodium salt of (2,6-dichlorophenyl)amide carbopentoxysulfanilic acid is characterized in that the reaction mass formed during the production of (2,6-dichlorophenyl)amide carbopentoxysulfanilic acid is agitated in a medium which is acidified with a solution of hydrochloric acid to pH 5-5.5, and the isolated precipitate may be washed with water acidified with a solution of hydrochloric acid to pH 5-5.5. This increases the yield of a sodium salt of (2,6-dichlorophenyl)amide carbopentoxysulfanilic acid to 70% (compared to a prior art yield of 32%) and also increases the purity of the target sodium salt.

Abstract: The invention relates to medicine, in particular to gastroenterology, and lies in the field of treatment of liver diseases of various origins. For this purpose, the hepatoprotective agent that is introduced to the patient is embodied as derivatives of bis(2-thio-4,6-dioxo-1,2,3,4,5,6-hexahydropyrimidine-5-yl) arylmethanes. The method provides reduction of the manifestations of cytolysis under the influence of damaging agents and a statistically significant reduction of dysproteinemia, it accelerates restoration of detoxifying processes of the liver, increases induction of endogenic interferon alfa and, consequently, makes the protection of liver cells during hepatitides of various origins more effective.

Abstract: The invention relates to fungicides and can be used for treating diseases caused by fungi, and also for preventing fungal damage to various materials and agricultural products. Claimed is an agent against fungal infections which is in the form of salts of 2,4-dioxo-5-arylideneamino-6-methyl-1,3-pyrimidine, where R is 4-NO2, 2-OH-5-NO2, 2-OH-3,5-Cl2, 5-Br-4-OH-3-OCH3, 2-OH-5-Cl, 2,4-Cl2, 3,5-Br2-2-OH. The result is an agent against fungal infections which has a broad spectrum of activity and is highly soluble, rendering it more effective for use in the form of solutions.

Abstract: The invention relates to medicine and can be used for treating a range of diseases in the treatment of which interferon is used. The agent for inducing endogenous interferon is comprised of the compound 6-(3-methoxycarbonyl phenyl) amino-2,4 (1H, 3H)-pyrimidinedione C12H11N3O4 of general formula: (I). The preparation exhibits greater activity both when injected and when administered orally.